Saturday 7 November 2026 Export QTTB’s income statement to Excel — free account

Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.

EPS: +43.6%
Free cash flow: +71.1%
Total debt: −35.6%

Quarter to June 2026, against a year earlier

Insider buying

9.25 0.40 +4.52%

Follow QTTB

Alert me

Market cap: $263.5M
P/E: 3.1×
Fwd P/E: −6.2×
Dividend yield: —
F-score: n/a
Altman Z: −0.78
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 30.00

Sold, $m 0.51

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	2	—	—	—	—	—	—
Sell	2	—	3	—	—	—	—	—	3	—	3	—

Insider Ownership 5.37%

Capital & Financial Ratios $m

Size

Market Cap 263.46

Revenue ttm (6.65)

Net income ttm 33.79

Free cash flow ttm (19.83)

Net debt Q (106.27)

Valuation

P/E 3.07

Forward P/E (6.16)

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.78

Financial health

Current ratio Q 20.30

Debt / equity Q 0.00

Interest coverage Q (5.48)

Growth

Revenue growth Q −1,928.18%

Operating income growth Q +0.58%

EPS, this year −156.40%

EPS, next year A −51.56%

Revenue, next year A −99.38%

EPS, past 5 yrs —

EPS, next 5 yrs A +9.95%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 43.16%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	78	48	106
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	29	82	55	110

	2023	2024	2025	Q'26
Payables	3	3	1	2
ST’ Debt	1	3	6	—
Other	—	3	—	—
	14	16	11	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	100.32%	16.52%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(26.51%)	(38.20%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.36 Actual −0.26

−1.52 −0.06 1.40 2.86 4.32

Q4 FY25 Beat +4.50

Q1 FY26 Miss −0.02

Q2 FY26 Beat +0.09

Q3 FY26 Beat +0.10

Q4 FY26 — Mar 9

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.85	3.65	Beat by 4.50
Q1 FY26	−0.52	−0.54	Miss by 0.02
Q2 FY26	−0.53	−0.44	Beat by 0.09
Q3 FY26	−0.36	−0.26	Beat by 0.10
Q4 FY26	−0.30	—	Reports 9 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.54)	(0.44)	—	—	—
’25	(0.90)	(0.78)	(0.60)	4.58	2.42
’24	0.44	(1.42)	(1.46)	(1.16)	(6.58)
’23	(19.84)	(16.69)	(40.52)	(76.91)	(153.96)
’22	28.60	(9.17)	(10.61)	(10.79)	(1.62)
’21	(0.36)	(9.71)	(9.71)	(10.61)	(31.11)
’20	(14.03)	(14.03)	(11.15)	(11.15)	(50.36)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	54
’23	3	3	2	(15)	(7)
’22	1	1	1	1	3
’21	29	2	2	1	34
’20	1	1	1	1	3
’19	0	0	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(12)	(11)	(4)	(6)	(34)
’24	(15)	(22)	(20)	(11)	(68)
’23	(12)	(11)	16	(11)	(19)
’22	(31)	(31)	(25)	(27)	(114)
’21	(30)	(24)	(25)	(30)	(110)
’20	(26)	(28)	(29)	(12)	(94)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(12)	(11)	(4)	1	(27)
’24	(15)	(22)	(20)	(11)	(68)
’23	(13)	(11)	16	(11)	(19)
’22	(32)	(31)	(25)	(27)	(115)
’21	(31)	(25)	(26)	(31)	(112)
’20	(28)	(29)	(29)	(13)	(98)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	5	2	3	34	3	(7)	—	54	(7)		+39.1%	0	1	2	(68.6%)
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	—	100.00	100.00		+100.0 pt	Powerpack Q32 Bio Inc.’s next three years, line by line Analysts expect revenue to shrink 68.6% a year to 2028 — slower than the 39.1% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(8)	(30)	(56)	(104)	(129)	(96)	1	(53)	(46)	30	34		n/m
	EBT margin, %	0.00	0.00	(1,044.29)	(6,237.45)	(4,762.92)	(281.90)	37.34	803.26	0.00	55.49	0.00		+55.5 pt
	Net income	(8)	(30)	(56)	(104)	(129)	(96)	(5)	(54)	(48)	30	34		n/m
Per share, $
Per share, $	Revenue	0.00	0.00	3.35	0.71	1.06	11.05	1.01	(19.05)	0.00	4.37	0.00		n/m
	Earnings	(76.13)	(217.59)	(35.97)	(44.42)	(50.36)	(31.11)	(1.62)	(153.96)	(5.12)	2.42	3.02		n/m
	Cash flow	(80.27)	47.02	(26.81)	(39.01)	(36.96)	(35.71)	(35.61)	(53.50)	(7.26)	(2.73)	(0.97)		(31.3%)
	Capex	(18.82)	(14.21)	(15.71)	(9.32)	(1.46)	(0.78)	(0.40)	(0.01)	(0.01)	0.57	0.00		n/m
	Free cash flow	(99.09)	32.81	(42.52)	(48.33)	(38.42)	(36.48)	(36.02)	(53.51)	(7.27)	(2.16)	(0.97)		(34.6%)
	Book value	70.96	713.41	123.69	110.39	76.78	55.19	55.77	(204.74)	0.61	3.42	5.21		(28.6%)
	Shares, m	0	0	2	2	3	3	3	0	9	12	15		+69.6%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—	1.43	3.07		0.2
	P/S	—	—	120.05	523.70	191.96	5.93	21.49	0.00	—	0.00	0.00		123.3
	P/B	—	—	3.25	3.38	2.65	1.19	0.39	0.00	—	0.97	1.78		1.7
	EV/Sales	—	—	79.70	366.20	117.21	2.04	(23.88)	(3.34)	—	(0.34)	(13.63)		76.8
	EV/FCF	—	—	(6.28)	(5.39)	(3.23)	(0.62)	0.67	(1.19)	—	(0.08)	(7.03)		(2.3)
Cash, $m
Cash, $m	Operating cash flow	(8)	6	(43)	(91)	(94)	(110)	(114)	(19)	(68)	(34)	(20)		+16.5%
	Capex	(2)	(2)	(25)	(22)	(4)	(2)	(1)	0	0	7	7		n/m
	Free cash flow	(10)	5	(68)	(113)	(98)	(112)	(115)	(19)	(68)	(27)	(20)		+10.9%
Balance, $m
Balance, $m	Working capital	6	123	199	254	197	175	158	15	65	44	104		+25.6%
	Net debt	(11)	(130)	(215)	(262)	(202)	(132)	(146)	18	(65)	(39)	(106)		+14.5%
	Shareholders’ equity	8	98	196	259	196	170	178	(71)	6	42	106		+21.1%
Returns, %
Returns, %	ROA	(10.61)	(39.53)	(28.03)	(36.48)	(44.82)	(40.28)	(2.27)	(39.01)	(68.49)	38.70	37.13		+49.3 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	(159.02)	(256.87)	0.00	0.00	308.43	0.00		+308.4 pt
	ROE	32.61	121.55	(70.84)	(45.69)	(56.63)	(52.38)	(2.88)	2,174.51	53.86	125.06	72.14		+92.4 pt
People
People	Employees	—	67	124	187	205	224	92	7	42	24	—		(12.0%)
	Revenue/emp, $m	—	0.00	0.04	0.01	0.01	0.15	0.03	(0.95)	0.00	2.24	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2023 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NAUT Nautilus Biotechnology, Inc.	$273.9M	— (loss-making)	—	—	n/m	−28.59% (below 0%: shrinking)	89.74%	(7,152.56%)	Compare
IPSC Century Therapeutics, Inc.	$273.4M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
TTRX Turn Therapeutics Inc.	$273.0M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
VOGX Vogenx Inc	$270.8M	—	—	—	n/m	—	—	0.00%	Compare
SABS SAB Biotherapeutics, Inc.	$267.5M	— (loss-making)	19.9×	−90.95% (below 0%: shrinking)	n/m	−59.75% (below 0%: shrinking)	100.00%	0.00%	Compare
RCKT Rocket Pharmaceuticals, Inc.	$267.3M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
ARCT Arcturus Therapeutics Holdings Inc.	$266.0M	— (loss-making)	— (loss-making)	+6.68% (above 0%: growing)	n/m	+59.86% (above 0%: growing)	100.00%	(50.20%)	Compare
SPRY ARS Pharmaceuticals, Inc.	$263.5M	— (loss-making)	— (loss-making)	+16.03% (above 0%: growing)	n/m	+36.52% (above 0%: growing)	0.00%	(90.62%)	Compare
QTTB Q32 Bio Inc.	$263.5M	3.1×	— (loss-making)	−1,928.18% (below 0%: shrinking)	n/m	+71.13% (above 0%: growing)	100.00%	0.00%
Median of peers	$269.2M	—	—	+11.36%	—	+19.16%	94.87%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 34.46%

Diyong Xu 14.76%

OrbiMed Private Investments VII, LP 14.41%

David Grayzel, M.D. 13.87%

Entities affiliated with Atlas Venture 13.39%

Sirenia Capital Management LP 9.99%

Entities affiliated with Opaleye Management Inc. 8.04%

Abingworth Bioventures VII LP 7.06%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Q32 Bio Inc. (QTTB) Latest News

4 Nov

Impact 3 · 6:59 AM · PR Newswire

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

30 Sep

Impact 4 · 9:15 AM · PR Newswire

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

21 Sep

Impact 4 · 9:15 AM

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

5 Aug

Impact 3 · 6:59 AM

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

31 Jul

Impact 3 · 9:55 AM

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

14 Jul

Impact 4 · 10:58 PM

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Impact 4 · 9:04 AM · qz.com

Q32 Bio stock surges 83% on positive alopecia drug trial data

Impact 4 · 6:14 AM

Q32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valued

13 Jul

Impact 4 · 9:58 PM · The Motley Fool

Why Q32 Bio Stock Skyrocketed Today

Impact 4 · 5:00 PM · Stocktwits

QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upside

Impact 4 · 12:02 PM · MarketBeat

Q32 Bio’s Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Study

Impact 4 · 8:24 AM · InvestorsHub

Q32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB)

Impact 4 · 8:03 AM · biopharmadive.com

Q32 bounces back to claim study success for alopecia drug

Impact 4 · 6:59 AM

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

Impact 3 · 4:01 PM

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

10 Jul

Impact 4 · 4:05 PM

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

27 May

Impact 4 · 1:55 PM · Stocktwits

QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism?

Impact 4 · 11:53 AM · InvestorsHub

Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)

Impact 3 · 8:00 AM · PR Newswire

Q32 Bio Announces $55 Million Private Placement Financing

8 May

Impact 4 · 9:55 AM · Zacks

Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade

5 May

Impact 3 · 6:59 AM · PR Newswire

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

30 Mar

Impact 4 · 9:55 AM · Zacks

Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?

19 Mar

Impact 4 · 12:00 PM · Zacks

Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know

13 Mar

Impact 3 · 9:55 AM · Zacks

Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

10 Mar

Impact 4 · 6:59 AM · PR Newswire

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Impact 3 · 7:14 AM · Associated Press Finance

Q32 Bio: Q4 Earnings Snapshot

1 Mar

Impact 4 · 12:34 PM · MarketBeat

Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab

17 Feb

Impact 4 · 6:59 AM · PR Newswire

Q32 Bio Announces $10.5 Million Registered Direct Offering

2 Dec

Impact 4 · 11:28 AM · Barchart

This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

1 Dec

Impact 3 · 1:32 PM · MT Newswires

Top Midday Gainers

Q32 Bio Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Q32 Bio Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Q32 Bio Inc. (QTTB) Latest News

4 Nov

30 Sep

21 Sep

5 Aug

31 Jul

14 Jul

13 Jul

10 Jul

27 May

8 May

5 May

30 Mar

19 Mar

13 Mar

10 Mar

1 Mar

17 Feb

2 Dec

1 Dec

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Q32 Bio Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Q32 Bio Inc. (QTTB) Latest News

4 Nov

30 Sep

21 Sep

5 Aug

31 Jul

14 Jul

13 Jul

10 Jul

27 May

8 May

5 May

30 Mar

19 Mar

13 Mar

10 Mar

1 Mar

17 Feb

2 Dec

1 Dec

Stockrow Weekly